NepalTuberculosis profile
Population  2014 28 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.9 (3.4–6.7) 17 (12–24)
Mortality (HIV+TB only) 0.38 (0.28–0.5) 1.4 (1–1.8)
Prevalence  (includes HIV+TB) 60 (29–100) 215 (102–369)
Incidence  (includes HIV+TB) 44 (39–50) 158 (139–178)
Incidence (HIV+TB only) 1.5 (1.2–1.9) 5.4 (4.2–6.7)
         
Case detection, all forms (%) 79 (71–90)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.3–3.8) 15 (10–23)
MDR-TB cases among notified pulmonary
TB cases
540 (320–930) 620 (410–920)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 15 947   2 302
Pulmonary, clinically diagnosed 8 445    
Extrapulmonary 8 583    
       
Total new and relapse 35 277    
Previously treated, excluding relapses 1 748    
Total cases notified 37 025    
Among 35 277 new cases:
345 (<1%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 292 (14%) 1 071 (26%) 3 396
Laboratory-confirmed RR-/MDR-TB cases     406
Patients started on MDR-TB treatment ***     349
TB/HIV 2014 Number (%)
TB patients with known HIV status 3 254 (9)
HIV-positive TB patients 369 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 273 (74)
HIV-positive people screened for TB 13 069  
HIV-positive people provided with IPT 43  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (91) 33 877
Previously treated cases, excluding relapse, registered in 2013 (74) 456
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (76) 238
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.9
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 22
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 15
% Funded domestically 56%
% Funded internationally 43%
% Unfunded 1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-27 Data: www.who.int/tb/data